scholarly journals Examining Tumor Growth Rates of Simple vs. Complex IDH Mutant Lower Grade Gliomas

2020 ◽  
Author(s):  
Teena Mary Thomas
Keyword(s):  
Tumor Growth ◽  
Growth Rates ◽  
Lower Grade

scholarly journals Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment

2020 ◽  
Vol 22 (12) ◽  
pp. 1822-1830
Author(s):  
Raymond Y Huang ◽  
Robert J Young ◽  
Benjamin M Ellingson ◽  
Harini Veeraraghavan ◽  
Wei Wang ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Growth Rates ◽  
World Health ◽  
Lower Grade ◽  
Volumetric Growth ◽  
Mixed Effect ◽  
Inversion Recovery Imaging ◽  
Significant Difference ◽  
Before And After

Abstract Background Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and/or 2 (IDH1/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and after treatment with established glioma therapies to determine whether a significant change in growth rate could be documented and perhaps be used in the future to evaluate treatment response to investigational agents in LGG trials. Methods In this multicenter retrospective study, 230 adult patients with IDH1/2 mutated LGGs (World Health Organization grade II or III) undergoing surgery, radiation, or chemotherapy for progressive non-enhancing tumor were identified. Subjects were required to have 3 MRI scans containing T2/fluid attenuated inversion recovery imaging spanning a minimum of 6 months prior to treatment. A mixed-effect model was used to estimate tumor growth prior to treatment. A subset of 95 patients who received chemotherapy, radiotherapy, or chemoradiotherapy and had 2 posttreatment imaging time points available were evaluated for change in pre- and posttreatment volumetric growth rates using a piecewise mixed model. Results The pretreatment volumetric growth rate across all 230 patients was 27.37%/180 days (95% CI: [23.36%, 31.51%]). In the 95 patients with both pre- and posttreatment scans available, there was a significant difference in volumetric growth rates before (26.63%/180 days, 95% CI: [19.31%, 34.40%]) and after treatment (−15.24% /180 days, 95% CI: [−21.37%, −8.62%]) (P < 0.0001). The growth rates for patient subgroup with 1p/19q codeletion (N = 118) was significantly slower than the rate of the 1p/19q non-codeleted group (N = 68) (22.84% vs 35.49%, P = 0.0108). Conclusion In this study, we evaluated the growth rates of IDH mutant gliomas before and after standard therapy. Further study is needed to establish whether a change in growth rate is associated with patient survival and its use as a surrogate endpoint in clinical trials for IDH mutant LGGs.

A multitype decomposable age-dependent branching process and its applications

1995 ◽  
Vol 32 (3) ◽  
pp. 591-608 ◽  
Author(s):  
Chinsan Lee ◽  
Grace L. Yang
Keyword(s):  
Tumor Growth ◽  
Life Span ◽  
Growth Rates ◽  
Exponential Growth ◽  
Branching Process ◽  
Asymptotic Formulas ◽  
Stage Model ◽  
Two Stage ◽  
Markov Branching Process ◽  
Age Dependent

Asymptotic formulas for means and variances of a multitype decomposable age-dependent supercritical branching process are derived. This process is a generalization of the Kendall–Neyman–Scott two-stage model for tumor growth. Both means and variances have exponential growth rates as in the case of the Markov branching process. But unlike Markov branching, these asymptotic moments depend on the age of the original individual at the start of the process and the life span distribution of the progenies.

A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS3127-TPS3127
Author(s):  
Ravi Amrit Madan ◽  
Nishith K. Singh ◽  
Ann Wild Gramza ◽  
Antonio Tito Fojo ◽  
Christopher Ryan Heery ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Growth ◽  
Phase Ii ◽  
Cancer Vaccine ◽  
Growth Rates ◽  
Medullary Thyroid Cancer ◽  
Phase Ii Study ◽  
Therapeutic Cancer Vaccine ◽  
Long Term Outcome ◽  
Medullary Thyroid

TPS3127 Background: Saccharomyces cerevisiae has been genetically modified to express CEA protein and developed under a CRADA with GlobeImmune/NCI as a heat-killed immune-stimulating, therapeutic cancer vaccine (GI-6207). A phase I study with GI-6207 demonstrated safety, biomarker stabilization and enhanced immune response in some patients. CEA is over-expressed in multiple malignancies, including medullary thyroid cancer (MTC). Two therapies recently approved by the FDA for metastatic MTC (vandetanib, cabozantinib) come with toxicity and should be reserved for symptomatic/progressive disease. However, a large population of asymptomatic MTC patients has small tumor burden and/or disease that is more indolent. The standard management of these patients is observation. Preliminary data suggest that tumor growth measured by the rate of CEA and calcitonin increase can be quantified in a 3-6 months. Retrospective data from prostate cancer studies suggest vaccines can alter growth rates within 3-4 months. We hypothesize that GI-6207 can alter tumor growth rates in MTC and impact long-term outcome. Methods: A phase II study will evaluate the effect of GI-6207 onthe rates ofincrease in calcitonin in metastatic MTC. 34 patients with minimally symptomatic, radiographically evaluable, metastatic MTC will be randomized 1:1. Arm A will receive vaccine for a year from the time of enrollment. Arm B will receive vaccine after 6 months of surveillance. GI-6207 will be administered subcutaneously at 4 sites (10 yeast units/site), every 2 weeks for 3 months, then monthly up to 1 year. The primary endpoint will compare the effect of GI-6207 on calcitonin kinetics between the vaccine and surveillance arms in the first 6 months. Secondary endpoints include immunologic responses (including antigen-specific T cell responses), objective responses, time to progression, and changes in CEA kinetics. If this trial can prospectively demonstrate that vaccines can alter tumor growth rates, and if such changes are associated with clinical outcomes, then changes in tumor growth rates may become a clinical metric to evaluate vaccine efficacy in MTC and other populations.

The Natural History of Incidental Meningiomas

Neurosurgery ◽  
2003 ◽  
Vol 53 (1) ◽  
pp. 62-71 ◽  
Author(s):  
Makoto Nakamura ◽  
Florian Roser ◽  
Julia Michel ◽  
Cornelius Jacobs ◽  
Madjid Samii
Keyword(s):  
Growth Rate ◽  
Natural History ◽  
Tumor Growth ◽  
Growth Rates ◽  
Tumor Size ◽  
Annual Growth ◽  
Tumor Doubling Time ◽  
History Of ◽  
Doubling Times ◽  
Initial Tumor Size

Abstract OBJECTIVE Little information about the natural history of incidental meningiomas exists in the literature. The aim of this study was to determine the natural history of asymptomatic meningiomas by comparing different methods of growth rate calculation to establish a strategy for dealing with these tumors. METHODS In 47 asymptomatic patients, hospital charts, follow-up records, and imaging studies were reviewed. Of these patients, 6 underwent surgery. Tumor growth rates were determined by calculating the absolute and relative growth rates and the tumor volume doubling times. RESULTS In 41 patients with conservative management, the average tumor size was 9 cm3, and the majority (66%) of growth rates were less than 1 cm3/yr. The absolute growth rate ranged from 0.03 to 2.62 cm3/yr (mean, 0.796 cm3/yr). Relative annual growth rates ranged from 0.48 to 72.8% (mean, 14.6%). The tumor doubling time ranged from 1.27 to 143.5 years (mean, 21.6 yr). A moderate correlation between the age and growth rates was found. In young patients, annual growth rates tended to be higher and tumor doubling times shorter. There was no clear correlation between the initial tumor size and tumor doubling time. The mean annual growth rate of meningiomas with calcification was lower than in tumors without calcification. Also, tumors with hypointense or isointense T2 signals on magnetic resonance imaging had a lower growth rate. In the group of six patients with surgical excision, tumor growth rates were higher and tumor doubling times shorter than in the nonsurgical group. CONCLUSION The majority of incidental meningiomas show minimal growth; thus, they may be observed without surgical intervention unless specific symptoms appear. Tumor growth is associated with patient age. The initial tumor size is not considered a predictive factor for tumor growth. Radiological features, such as calcification or T2 signal intensity, may provide useful information to predict the growth potential of meningiomas.

scholarly journals Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data

2008 ◽  
Vol 13 (10) ◽  
pp. 1046-1054 ◽  
Author(s):  
Wilfred D. Stein ◽  
William Doug Figg ◽  
William Dahut ◽  
Aryeh D. Stein ◽  
Moshe B. Hoshen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Tumor Growth ◽  
Growth Rates ◽  
Patient Survival ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Novel Strategy

scholarly journals Using Free-Range Laboratory Mice to Explore Foraging, Lifestyle, and Diet Issues in Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Douglas F. Makin ◽  
Ella Agra ◽  
Manu Prasad ◽  
Joel S. Brown ◽  
Moshe Elkabets ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cancer Progression ◽  
Growth Rates ◽  
Laboratory Mouse ◽  
Disease Status ◽  
Climatic Conditions ◽  
Activity Levels ◽  
Laboratory Mice ◽  
Free Range ◽  
Free Ranging

As cancer progresses, its impact should manifest in the foraging behavior of its host much like the effects of endo-parasites that hinder foraging aptitudes and risk management abilities. Furthermore, the lifestyle of the host can impact tumor growth and quality of life. To approach these questions, we conducted novel experiments by letting C57BL/6 laboratory mice, with or without oral squamous cell carcinoma, free range in a large outdoor vivarium. Our goals were to: (1) determine whether one could conduct experiments with a mouse model under free range conditions, (2) measure effects of cancer burden on foraging metrics, (3) compare tumor growth rates with laboratory housed mice, and (4) begin to sort out confounding factors such as diet. With or without cancer, the C57BL/6 laboratory mice dealt with natural climatic conditions and illumination, found shelter or dug burrows, sought out food from experimental food patches, and responded to risk factors associated with microhabitat by foraging more thoroughly in food patches under bush (safe) than in the open (risky). We quantified foraging using giving-up densities of food left behind in the food patches. The mice’s patch use changed over time, and was affected by disease status, sex, and microhabitat. Males, which were larger, consumed more food and had lower giving-up densities than females. Relative to cancer-free mice, mice with growing tumors lost weight, harvested more food, and increasingly relied on patches in the bush microhabitat. The tumors of free-ranging mice in the vivarium grew slower than those of their cohort that were housed in mouse cages in animal facilities. Numerous interesting factors could explain the difference in tumor growth rates: activity levels, stress, weather, food intake, diet, and more. To tease apart one of these intertwined factors, we found that tumors grew faster when mice in the laboratory were fed on millet rather than laboratory mouse chow. While just a start, these novel experiments and framework show how free-ranging mice provide a model that can test a broader range of hypotheses and use a broader range of metrics regarding cancer progression and its consequences for the host.

Sign in / Sign up

Export Citation Format

Share Document